View highlights and coverage from leading international congresses
It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to discuss study results investigating subcutaneous human immunoglobulin 16.5% in patients with primary immunodeficiencies. The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) was presented at the […]
It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to give us an overview of immunoglobulin replacement therapy, and subcutaneous human IgG 16.5% in patients with immunodeficiencies. The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) […]
It was a pleasure to talk to Stephen Hanauer (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around his presentation on ‘EMERGING IBD THERAPIES’ which was presented at the virtual 2021 Crohn’s & Colitis Congress. Questions Could you give us a brief overview of the current treatment options for patients with moderate‑to‑severe ulcerative colitis […]
We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD. Questions What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination […]
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)’ was presented at the virtual ACR […]
TouchIMMUNOLOGY got the chance to catch up with Hans Prenen (University Hospital Antwerp, Edegem, Belgium) around the potential advantages of non-gene edited allogeneic CAR T cell therapy (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was […]
Russell Cohen (University of Chicago Medicine, Chicago, IL, US) spoke with touchIMMUNOLOGY around the optimal use of available therapies in the treatment of IBD. ‘Positioning Tofacitinib and Other Available Therapies’ was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021. Questions Could you tell us a little about tofacitinib and its available […]
TouchIMMUNOLOGY were delighted to talk to Ken Kato at ASCO’s virtual Gastrointestinal Cancers Symposium 2021 to discuss the potential role of nivolumab in the treatment of gastrointestinal cancers, and how the identification of biomarkers is key to improve clinical response. For more information on the 5-year follow-up data presented at ASCO’s Gastrointestinal Cancer’s Symposium, please […]
It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis. The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The […]
Get the latest clinical insights from touchIMMUNOLOGY
